Business Description
Sinopharm Group Co Ltd
ISIN : CNE100000FN7
Share Class Description:
SHTDF: HTotal Employee Number:
94,910Compare
Compare
Traded in other countries / regions
01099.Hong KongSHTDY.USAX2S.Germany IPO Date
2009-11-16Description
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.69 | |||||
Equity-to-Asset | 0.22 | |||||
Debt-to-Equity | 0.85 | |||||
Debt-to-EBITDA | 3.34 | |||||
Interest Coverage | 7.43 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 2.24 | |||||
Beneish M-Score | -2.47 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1 | |||||
3-Year EBITDA Growth Rate | -6.9 | |||||
3-Year EPS without NRI Growth Rate | -6.4 | |||||
3-Year FCF Growth Rate | -12.6 | |||||
3-Year Book Growth Rate | 6.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 8.65 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 4.58 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 16.07 | |||||
9-Day RSI | 25.09 | |||||
14-Day RSI | 27.41 | |||||
3-1 Month Momentum % | -14.5 | |||||
6-1 Month Momentum % | -12.03 | |||||
12-1 Month Momentum % | 4.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.41 | |||||
Quick Ratio | 1.15 | |||||
Cash Ratio | 0.2 | |||||
Days Inventory | 43.49 | |||||
Days Sales Outstanding | 129.46 | |||||
Days Payable | 104.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 4.41 | |||||
Dividend Payout Ratio | 0.25 | |||||
3-Year Dividend Growth Rate | -3.6 | |||||
Forward Dividend Yield % | 4.41 | |||||
5-Year Yield-on-Cost % | 4.53 | |||||
Shareholder Yield % | 12.84 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 7.25 | |||||
Operating Margin % | 2.97 | |||||
Net Margin % | 1.24 | |||||
EBITDA Margin % | 3.72 | |||||
FCF Margin % | 2.31 | |||||
OCF Margin % | 2.6 | |||||
ROE % | 8.91 | |||||
ROA % | 1.8 | |||||
ROIC % | 6.62 | |||||
3-Year ROIIC % | -23.78 | |||||
ROC (Joel Greenblatt) % | 14.31 | |||||
ROCE % | 12.14 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 3 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 6.26 | |||||
Forward PE Ratio | 6.22 | |||||
PE Ratio without NRI | 5.39 | |||||
Shiller PE Ratio | 5.91 | |||||
Price-to-Owner-Earnings | 5.94 | |||||
PS Ratio | 0.08 | |||||
PB Ratio | 0.53 | |||||
Price-to-Tangible-Book | 0.6 | |||||
Price-to-Free-Cash-Flow | 3.45 | |||||
Price-to-Operating-Cash-Flow | 3.07 | |||||
EV-to-EBIT | 6.91 | |||||
EV-to-Forward-EBIT | 9.74 | |||||
EV-to-EBITDA | 5.52 | |||||
EV-to-Forward-EBITDA | 8.6 | |||||
EV-to-Revenue | 0.21 | |||||
EV-to-Forward-Revenue | 0.27 | |||||
EV-to-FCF | 9.11 | |||||
Price-to-GF-Value | 0.75 | |||||
Price-to-Projected-FCF | 0.24 | |||||
Price-to-Median-PS-Value | 0.64 | |||||
Price-to-Graham-Number | 0.38 | |||||
| Price-to-Net-Current-Asset-Value | 1.1 | |||||
Earnings Yield (Greenblatt) % | 14.47 | |||||
FCF Yield % | 28.95 | |||||
Forward Rate of Return (Yacktman) % | 23.11 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:SHTDF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sinopharm Group Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 80,886.854 | ||
| EPS (TTM) ($) | 0.323 | ||
| Beta | -0.3982 | ||
| 3-Year Sharpe Ratio | -0.34 | ||
| 3-Year Sortino Ratio | -0.47 | ||
| Volatility % | 30.26 | ||
| 14-Day RSI | 27.41 | ||
| 14-Day ATR ($) | 0.004544 | ||
| 20-Day SMA ($) | 2.2872 | ||
| 12-1 Month Momentum % | 4.8 | ||
| 52-Week Range ($) | 2.11 - 2.7 | ||
| Shares Outstanding (Mil) | 3,120.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sinopharm Group Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sinopharm Group Co Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-10-27 | In 124 days | ||
| Second quarter earnings results for 2026 | 2026-08-25 | In 61 days | ||
| HKD 0.790000 Cash Dividend | 2026-06-23 | 2.29 (+0.00%) | ||
| General meeting for 2025 | 2026-06-18 09:00 | 2.29 (+0.00%) | ||
| Annual report for 2025 | 2026-04-24 | 2.68 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-10-27 | 2.50 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-25 | 2.29 (+0.00%) | ||
| HKD 0.739000 Cash Dividend | 2025-06-16 | 2.18 (+0.00%) | ||
| General meeting for 2024 | 2025-06-12 09:00 | 2.18 (+0.00%) | ||
| Annual report for 2024 | 2025-04-25 | 2.15 (+0.00%) |
Show
Entries
Sinopharm Group Co Ltd Frequently Asked Questions
What is Sinopharm Group Co Ltd(SHTDF)'s stock price today?
The current price of SHTDF is $2.29. The 52 week high of SHTDF is $2.70 and 52 week low is $2.11.
When is next earnings date of Sinopharm Group Co Ltd(SHTDF)?
The next earnings date of Sinopharm Group Co Ltd(SHTDF) is 2026-08-25 Est..
Does Sinopharm Group Co Ltd(SHTDF) pay dividends? If so, how much?
The Dividend Yield %  of Sinopharm Group Co Ltd(SHTDF) is 4.41% (As of Today), Highest Dividend Payout Ratio of Sinopharm Group Co Ltd(SHTDF) was 0.31. The lowest was 0.21. And the median was 0.25. The  Forward Dividend Yield % of Sinopharm Group Co Ltd(SHTDF) is 4.41%. For more information regarding to dividend, please check our Dividend Page.
Guru Commentaries on OTCPK:SHTDF
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Sinopharm Group Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers